Abstract. Objectives. The folate antagonist methotrexate (MTX) has become established as the most commonly used disease-modifying anti-rheumatic drugAbstract. Objectives. The folate antagonist methotrexate (MTX) has become established as the most commonly used disease-modifying anti-rheumatic drugAbstract. Objectives. The folate antagonist methotrexate (MTX) has become established as the most commonly used disease-modifying anti-rheumatic drug